Auto-Commentary on: "Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells".

Autor:	de Beauchamp L; Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, College of Medical, Veterinary & Life Sciences, University of Glasgow, Glasgow UK., Baquero P; Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, College of Medical, Veterinary & Life Sciences, University of Glasgow, Glasgow UK., Kuntz EM; Cancer Research UK, Beatson Institute, Garscube Estate, Switchback Road, Glasgow, UK., Gottlieb E; Cancer Research UK, Beatson Institute, Garscube Estate, Switchback Road, Glasgow, UK.; Technion Integrated Cancer Center, Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel., Helgason GV; Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, College of Medical, Veterinary & Life Sciences, University of Glasgow, Glasgow UK.
Jazyk:	angličtina
Zdroj:	Molecular & cellular oncology [Mol Cell Oncol] 2017 Dec 18; Vol. 5 (1), pp. e1403532. Date of Electronic Publication: 2017 Dec 18 (Print Publication: 2018).
DOI:	10.1080/23723556.2017.1403532
Abstrakt:	We have recently uncovered an abnormal increase in mitochondrial oxidative metabolism in therapy-resistant chronic myeloid leukaemia stem cells (LSCs). By simultaneously disrupting mitochondrial respiration and inhibiting BCR-ABL kinase activity using the antibiotic tigecycline and imatinib respectively, we effectively eradicated LSCs and prevented disease relapse in pre-clinical animal models.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu